A method for treating a hangover, comprising of administering to a subject in need a powdered or liquid juice product containing juiced ingredients of red onion, cucumber, and romaine lettuce. Other embodiments contain onion, cucumber, and one or more of any other leafy green vegetable. The components of the applicant's invention create a novel synergistic effect because the combination creates a greater effect than the sum of the effects of the components separately.

Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.

The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.

Methods for alleviating, reversing or inhibiting one or more symptom of post-polio syndrome via administration of a composition comprising egg yolk powder are provided.

Methods for alleviating, reversing or inhibiting one or more symptom of post-polio syndrome via administration of a composition comprising egg yolk powder are provided.

The invention relates to a pharmaceutical composition and the method of preparing the pharmaceutical composition, wherein the composition comprises an oil-in-water emulsion of an exosome, such as a mesenchymal stem cell (MSC) exosome, for the treatment or prevention of a dermatological disease or condition, such as psoriasis.

A process for obtaining biologically active compositions from emu oil is provided, wherein the compositions are obtained by molecular distillation of the oil, both the distillate and the distillation residue being biologically active compositions. More specifically, a process for obtaining biologically active compositions from refined emu oil is disclosed, which has the following steps: (a) feeding emu oil at a flow of between 1 to 300 kg/h*m2 to a molecular distillation column at a pressure between 0.0001 mbar and 0.05 mbar and at an evaporator temperature between 160° C. and 250° C., for generating a distillate and a residue; and (b) collecting the distillate from the column, the distillate being a biologically active composition, and (c) collecting the residue from the column, the residue being a biologically active composition.